Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 10/20 | 0.47 |
| ▸ | PNP | P00491 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PI4KA | P42356 | 1/20 | 0.40 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.40 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24767723 | 0.88 | PNP (0.47) | HPRT1PNPLMNAMEN1KMT2A | |
| SCHEMBL23774611 | 0.88 | HPRT1 (0.47) | HPRT1PNPLMNAMEN1KMT2A | |
| SCHEMBL23934886 | 0.86 | PNP (0.46) | HPRT1PNPLMNAMEN1KMT2A | |
| SCHEMBL13657243 | 0.84 | PI4KA (0.51) | HPRT1PNPLMNAMEN1KMT2A | |
| SCHEMBL21372049 | 0.84 | PNP (0.44) | HPRT1PNPLMNAMEN1KMT2A | |
| SCHEMBL22883459 | 0.81 | HPRT1 (0.46) | HPRT1PNPLMNAMEN1KMT2A | |
| SCHEMBL21417467 | 0.79 | PNP (0.46) | HPRT1PNPLMNAMEN1KMT2A | |
| SCHEMBL18769787 | 0.78 | MEN1 (0.51) | HPRT1PNPLMNAMEN1KMT2A | |
| SCHEMBL23476793 | 0.75 | MEN1 (0.35) | PNPMEN1KMT2API4KAPI4K2B | |
| SCHEMBL1993930 | 0.74 | HPRT1 (0.63) | HPRT1PNPLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20210277046-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-09 | — | — | US | disclosed |
| US-10927394-B2 | Methods and reagents for synthesising polynucleotide molecules | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2021-02-23 | — | — | US | disclosed |
| US-20200369711-A1 | MODIFIED CYCLIC DINUCLEOSIDE COMPOUNDS AS STING MODULATORS | ALIGOS THERAPEUTICS, INC. | 2020-11-26 | — | — | US | disclosed |
| US-20190352687-A1 | METHODS AND REAGENTS FOR SYNTHESISING POLYNUCLEOTIDE MOLECULES | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2019-11-21 | — | — | US | disclosed |
| US-20190300561-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS | Epizyme, Inc. | 2019-10-03 | — | — | US | disclosed |
| US-20190185511-A1 | LOCKED NUCLEIC ACID CYCLIC DINUCLEOTIDE COMPOUNDS AND USES THEREOF | Aduro Biotech, Inc. (US) | 2019-06-20 | — | — | US | disclosed |
| US-9688714-B2 | Substituted purine compounds | Epizyme, Inc. (US) | 2017-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185511-A1 | LOCKED NUCLEIC ACID CYCLIC DINUCLEOTIDE COMPOUNDS AND USES THEREOF | STING1, TLR9, IFNAR1 | HPRT1 323/4885PNP 182/4885LMNA 474/4885 |
| US-20210277046-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, IFNAR1 | HPRT1 357/4885PNP 319/4885LMNA 653/4885 |
| US-20200369711-A1 | MODIFIED CYCLIC DINUCLEOSIDE COMPOUNDS AS STING MODULATORS | STING1, CGAS, IRF3 | HPRT1 380/4885PNP 95/4885LMNA 825/4885 |
| US-20190300561-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS | MECP2, DOT1L, DNMT1 | HPRT1 212/4885PNP 66/4885LMNA 3565/4885 |
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | STING1, CGAS, IRF3 | HPRT1 380/4885PNP 95/4885LMNA 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.